Key Points
- Director Bros. Advisors LP Baker made substantial purchases: Baker bought 15,666 shares for about $5.76 million at an average price of $367.71, increasing the position by 0.8%. The article also reports a subsequent purchase of 76,140 shares for about $29.26 million.
- Madrigal reported quarterly EPS of $1.83, versus analyst expectations of a $1.09 loss, and revenue of $431.3 million, above the $404.2 million estimate.
- Analysts’ consensus rating was Moderate Buy, with an average price target of $706.87; Canaccord raised its target to $633 and maintained a Buy rating.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) General Counsel Shannon Kelley sold 1,077 shares of the company's stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $400.00, for a total transaction of $430,800.00. Following the transaction, the general counsel owned 10,397 shares in the company, valued at $4,158,800. The trade was a 9.39% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Madrigal Pharmaceuticals Trading Down 0.1%
Shares of MDGL stock opened at $399.63 on Friday. The business's 50 day moving average is $486.74 and its two-hundred day moving average is $497.41. Madrigal Pharmaceuticals, Inc. has a twelve month low of $353.54 and a twelve month high of $615.00. The company has a market capitalization of $9.23 billion, a P/E ratio of -66.83 and a beta of -0.98. The company has a current ratio of 3.20, a quick ratio of 2.94 and a debt-to-equity ratio of 0.65.
Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 earnings per share for the quarter, topping the consensus estimate of ($1.09) by $2.92. The firm had revenue of $431.27 million for the quarter, compared to analyst estimates of $404.17 million. Madrigal Pharmaceuticals had a negative net margin of 25.32% and a negative return on equity of 56.65%. During the same quarter in the prior year, the business earned ($5.08) earnings per share. Equities analysts forecast that Madrigal Pharmaceuticals, Inc. will post -3.78 EPS for the current year.
Analysts Set New Price Targets
MDGL has been the subject of several analyst reports. Citigroup upped their price target on shares of Madrigal Pharmaceuticals from $725.00 to $760.00 and gave the company a "buy" rating in a research report on Tuesday. HC Wainwright assumed coverage on shares of Madrigal Pharmaceuticals in a research report on Wednesday. They issued a "strong-buy" rating for the company. Barclays dropped their price objective on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an "overweight" rating on the stock in a research note on Monday, August 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, October 15th. Finally, Canaccord Genuity Group increased their target price on shares of Madrigal Pharmaceuticals from $612.00 to $633.00 and gave the company a "buy" rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $706.87.
View Our Latest Stock Analysis on Madrigal Pharmaceuticals
Key Stories Impacting Madrigal Pharmaceuticals
Here are the key news stories impacting Madrigal Pharmaceuticals this week:
- Positive Sentiment: Multiple real-world studies presented at AASLD reported improvements in liver stiffness and cardiometabolic health markers among patients treated with Rezdiffra, supporting the drug’s real-world potential. Rezdiffra real-world data
- Positive Sentiment: Madrigal’s latest quarterly results beat estimates: EPS was $1.83 versus consensus of a $1.09 loss, and revenue of $431.3 million exceeded the $404.2 million estimate. Madrigal stock jumps after earnings beat
- Positive Sentiment: HC Wainwright reiterated a Strong-Buy rating and projected rising EPS through 2030; Canaccord Genuity also raised its price target to $633 and maintained a Buy rating. These forecasts point to optimism about future growth, though they are analyst expectations, not guarantees.
- Neutral Sentiment: General Counsel Shannon Kelley sold 1,077 shares for about $430,800 under a pre-arranged Rule 10b5-1 plan. Kelley retained 10,397 shares, which may temper concern about the sale.
- Negative Sentiment: Several law firms announced investigations into potential securities-law violations after Madrigal’s November 3 quarterly filing. These are investigations and investor solicitations—not findings of wrongdoing—but could create legal and reputational uncertainty. Securities investigation announcement
Hedge Funds Weigh In On Madrigal Pharmaceuticals
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. J. Goldman & Co LP acquired a new position in shares of Madrigal Pharmaceuticals during the second quarter worth $2,722,000. Royal Bank of Canada grew its holdings in shares of Madrigal Pharmaceuticals by 22.5% during the first quarter. Royal Bank of Canada now owns 12,526 shares of the biopharmaceutical company's stock worth $6,557,000 after buying an additional 2,303 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in shares of Madrigal Pharmaceuticals by 1,738.3% during the 2nd quarter. Hsbc Holdings PLC now owns 20,240 shares of the biopharmaceutical company's stock worth $10,868,000 after acquiring an additional 19,139 shares during the period. Sivik Global Healthcare LLC purchased a new stake in shares of Madrigal Pharmaceuticals during the third quarter valued at approximately $1,260,000. Finally, Legal & General Group Plc acquired a new stake in shares of Madrigal Pharmaceuticals during the 2nd quarter valued at approximately $6,630,000. Institutional investors own 98.50% of the company's stock.
About Madrigal Pharmaceuticals
(
Get Free Report)
Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal's lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
